ANCR.L Stock Analysis
AN
Neutral
Based on Eyestock quantitative analysis, ANCR.L`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Market cap $B
0.197
Dividend yield
2.94 %
Shares outstanding
60.092 B
Animalcare Group Plc engages in the development, sale, and supply of generic veterinary medicines and animal identification products. The company is headquartered in Ripon, North Yorkshire and currently employs 211 full-time employees. The company went IPO on 2008-01-15. The firm develops and commercializes trusted prescription and over-the-counter pharmaceutical products, which improve animal health and wellbeing. These are developed in-house, acquired from other companies or in-licensed from its partners. The firm manage an international supply chain, including specialist veterinary wholesalers and distributors. The company partners with companies to commercialize products across Europe. The firm operates in three categories within the veterinary market: Companion Animals, Equine and Production Animals. The company focuses the Company’s people and product investment on three main therapy areas: pain management, dermatology and non-antibiotic anti-infectives. The Company’s product pipeline is Daxocox, which is a differentiated COX-2 inhibitor for the treatment of chronic pain in dogs.